32th PAGE Meeting

Rome - Italy
26-28 June, 2024

View abstracts

Home / 2024 – Rome – Italy / Abstracts

← Back to filters

Abstracts (15)

I-018Asma Baliouze

Exposure-Response Analysis of Centanafadine Sustained Release Tablets in Adults with Attention-Deficit/Hyperactivity Disorder

Wednesday 10:20-11:50

I-032Monir Bertayli

PK-PD model of morphine, pregabalin and their combination to assess the opioid-sparing effect

Wednesday 10:20-11:50

I-061Lu Chen

Time-dependent pharmacokinetics of hydromethylthionine mesylate (HMTM), a tau aggregation inhibitor, in healthy volunteers and patients with Alzheimer’s Disease

Wednesday 10:20-11:50

I-113Aline Fuchs

Human dose prediction approach for a therapeutic monoclonal antibody for a CNS indication inferred using preclinical data including target occupancy

Wednesday 10:20-11:50

II-005Mohamed Gewily

Quantitative comparisons of Progressive Supranuclear Palsy rating scales versions using Item Response Theory modeling

Wednesday 15:20-16:50

II-039Maria Patricia Hernandez Mitre

Population pharmacokinetics of olanzapine and quetiapine in critically ill adults with delirium

Wednesday 15:20-16:50

II-049Silvia Illamola

Population analysis of blood-brain barrier heterogeneity and correlation with imaging characteristics in individuals with central nervous system malignancies.

Wednesday 15:20-16:50

III-007Victor Mangas-Sanjuan

Pharmacometric characterization of the reserpine-induced fibromyalgia model in rats to support a model-informed dosing regimen strategy for alternative disease status conditions

Thursday 09:50-11:20

III-062Noel Patson

Natural disease progression model with transition probabilities to describes the continuum of Alzheimer’s disease

Thursday 09:50-11:20

III-066Carlos Perez-Ruixo

A Mechanism-Based PK/PD Model for Posdinemab (JNJ-63733657), a Humanized Monoclonal Antibody Targeting pTau, in healthy and Alzheimer’s Disease Subjects

Thursday 09:50-11:20

III-094Elena Righetti

A mechanistic model of pure and lipid-mediated alpha-synuclein aggregation to advance therapeutic strategies against Parkinson’s disease

Thursday 09:50-11:20

III-101Chiara Roversi

Integrated Population PK and PBPK Modelling Approaches of IAMA-6 Plasma Concentrations following Oral, Intraperitoneal and Intravenous Administrations in Three Different Preclinical Species for First in Human Dose Prediction

Thursday 09:50-11:20

IV-023ming sun

Bayesian PBPK modeling for acyclovir dose optimization for treating viral encephalitis

Thursday 15:00-16:30

IV-056Marloes van Leuken

A population pharmacokinetic model of N,N-dimethyltryptamine administered through continuous intravenous infusion in healthy smokers and non-smokers

Thursday 15:00-16:30

IV-106Mengxu Zhang

Exploring the contribution of brain metabolism in mechanistic understanding of Kp,uu,BBB – A case study for remoxipride

Thursday 15:00-16:30